CLOs on the Move

Arcellx

www.arcellx.com

 
Arcellx, Inc. is a clinical-stage biotechnology company reimagining cell therapy by engineering innovative immunotherapies for patients with cancer and other incurable diseases. Arcellx believes that cell therapies are one of the forward pillars of medicine and Arcellx`s mission is to advance humanity by developing cell therapies that are safer, more effective, and more broadly accessible. Arcellx`s lead product candidate, CART-ddBCMA, is being developed for the treatment of relapsed or refractory multiple myeloma (r/r MM) in an ongoing Phase 1 study. CART-ddBCMA has been granted Fast Track, Orphan Drug, and Regenerative Medicine Advanced Therapy designations by the U.S. Food and Drug ...
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.arcellx.com
  • 25 West Watkins Mill Road Suite A
    Gaithersburg, MD USA 20878
  • Phone: 240.327.0603

Executives

Name Title Contact Details
Maryam Abdul-Kareem
General Counsel Profile

Similar Companies

STERIS

STERIS is the world's pre-eminent infection prevention, decontamination, and surgical and critical care company, with a long list of first-to-market products and industry-leading service innovations and thousands of customers in more than 60 countries.

DFM

DFM is a Morristown, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Novan Therapeutics

Novan is a clinical-stage drug development company focused on topical delivery of nitric oxide. The company`s proprietary platform technology enables the stable storage and release of nitric oxide in a variety of dosage forms. Novan is currently developing innovative, first-in-class therapies for the field of dermatology.

Lineage Cell

Lineage Cell Therapeutics is a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs. Lineage`s programs are based on its proprietary cell-based therapy platform and associated development and manufacturing capabilities. With this platform Lineage develops and manufactures specialized, terminally-differentiated human cells from its pluripotent and progenitor cell starting materials. These differentiated cells are developed either to replace or support cells that are dysfunctional or absent due to degenerative disease or traumatic injury or administered as a means of helping the body mount an effective immune response to cancer. Lineage`s clinical assets include (i) OpRegen®, a retinal pigment epithelium transplant therapy in Phase I/IIa development for the treatment of dry age-related macular degeneration, a leading cause of blindness in the developed world; (ii) OPC1, an oligodendrocyte progenitor cell therapy in Phase I/IIa development for the treatment of acute spinal cord injuries; and (iii) VAC2, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells currently in Phase I development for the treatment of non-small cell lung cancer.

Mango Materials

Mango Materials produces biodegradable plastics from waste biogas (methane) that are economically competitive with conventional, oil-based plastics. Mango Materials produces poly-hydroxyalkanoate (PHA) powder, a valuable biopolymer that is converted into a variety of ecofriendly, plastic products such as children’s toys, electronic casings, water bottles, and food packaging containers. Due to a rising preference for green products, demand for biodegradable and non petroleum-based plastics is growing rapidly. Mango Materials uses affordable methane gas and a process that competes favorably with petroleum-based plastics to produce low-cost, biodegradable plastics.